ENZAMET Trial Shows Veracyte's Decipher Prostate Test Identifies Which Patients Benefit from Adding Chemotherapy in Metastatic Prostate Cancer
Veracyte announced results from the ENZAMET trial presented at ASCO 2026, showing its Decipher Prostate test identifies which metastatic prostate cancer patients benefit from adding chemotherapy to standard hormonal therapy. The analysis of 634 patients provided Level 1B evidence with a statistically significant treatment-by-biomarker interaction (p=0.043), demonstrating that high-risk patients (>0.85 score) benefit from triplet therapy while lower-risk patients can safely avoid chemotherapy.
Key figures
- P value
- 0.043
- Enzamet patient count
- 634
- Reclassification rate
- 1 in 4
- Median follow up years
- 5.6
- Annual us total diagnoses
- 334000
- High risk score threshold
- 0.85
- Annual us metastatic diagnoses
- 30000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.